NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.
NRG Therapeutics has raised $67.5M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
NRG Therapeutics's investors include British Business Bank, Brandon Capital, Omega Funds, Dementia Discovery Fund, Michael J. Fox Foundation.
NRG Therapeutics is headquartered in Cambridge, United Kingdom.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.
NRG Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NRG Therapeutics — Funding & Investors." VCBacked, September 8, 2025, https://www.vcbacked.co/company/nrg-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). NRG Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/nrg-therapeutics
{{cite web |title=NRG Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nrg-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated